An upstate New York health center has sued the nation’s four major insulin manufacturers for allegedly conspiring to stop offering 340B pricing when covered entities use contract pharmacies.
Mosaic Health’s July 30 lawsuit claims that insulin manufacturers’ Sanofi, Eli
…
Boehringer Ingelheim (BI) on Sunday became the seventh drug manufacturer to deny 340B pricing on its products when hospitals contract with pharmacies to dispense the medicines, hospitals reported yesterday.
BI this morning confirmed that it has begun denying 340B pricing
…
340B covered entities dodged a bullet Sunday when U.S. Senate negotiators released the text of a $550 billion bipartisan infrastructure-spending bill. It did not contain Medicaid managed care “spread pricing” language that entities have been fending off since 2019. Entities
…
Attorneys for the government and drug manufacturer Eli Lilly dueled over the legality of 340B contract pharmacy requirements during a hearing before a federal district judge in Indianapolis today.
Stakeholders are watching the Lilly case closely because, given how far
…
An influential Republican congressman on Monday cautioned against amending federal spending legislation to rebuke six drug manufacturers’ denials of 340B pricing when covered entities use contract pharmacies.
During a July 26 U.S. House Rules Committee hearing, Rep. Michael Burgess (R-Texas)
…
AstraZeneca and the federal government have filed a new round of briefs in the drug manufacturer’s 340B contract pharmacy lawsuit, this round focused on the government’s May 17 letter telling the company its contract pharmacy actions are illegal.
In a
…
The 340B program “will not be overlooked” if the drug industry strikes a grand bargain with Congress and the Biden administration on lowering drug prices, biopharma policy analyst Michael McCaughan predicted this week during a talk on drug pricing reform
…
Drug manufacturer Novo Nordisk is giving 340B covered entities refunds for overcharges on two package sizes of its Tresiba FlexTouch insulin pen and on 10 milliliter vials of its Fiasp brand insulin.
The U.S. Health Resources and Services Administration (HRSA)
…
Retired U.S. Sen. Mike Enzi (R-Wy.), who co-led inquiries into stewardship of the 340B program while in Congress, died on Monday after being injured in a bicycle accident in his hometown of Gillette, Wyo. He was 77.
Enzi was a
…
The U.S. House voted this evening “to highlight the need to protect the integrity of the 340B program by halting pharmaceutical manufacturers’ unlawful actions that have resulted in overcharges to 340B covered entities.”
Reps. Abigail Spanberger (D-Va.) and David McKinley
…*Sign up for news summaries and alerts from 340B Report